Toronto Dominion Bank Acquires 4,218 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Toronto Dominion Bank grew its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 66,997 shares of the company's stock after purchasing an additional 4,218 shares during the period. Toronto Dominion Bank owned approximately 0.05% of Henry Schein worth $4,636,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Investment Management Corp VA ADV acquired a new position in shares of Henry Schein during the fourth quarter valued at $32,000. Venturi Wealth Management LLC increased its holdings in shares of Henry Schein by 3,347.1% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the company's stock valued at $41,000 after purchasing an additional 569 shares during the period. Quent Capital LLC boosted its stake in Henry Schein by 91.2% during the fourth quarter. Quent Capital LLC now owns 677 shares of the company's stock valued at $47,000 after buying an additional 323 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Henry Schein by 23.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after buying an additional 143 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in Henry Schein by 180.7% during the fourth quarter. Allworth Financial LP now owns 946 shares of the company's stock valued at $71,000 after buying an additional 609 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Down 2.9%

NASDAQ:HSIC traded down $2.12 on Friday, hitting $69.86. The stock had a trading volume of 3,123,095 shares, compared to its average volume of 1,672,150. The business's fifty day moving average is $67.65 and its 200 day moving average is $71.66. The company has a market cap of $8.50 billion, a PE ratio of 28.75, a P/E/G ratio of 2.13 and a beta of 0.87. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company's quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.10 earnings per share. On average, equities research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. This trade represents a 9.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the firm's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. This represents a 6.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Wells Fargo & Company dropped their price target on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Wall Street Zen lowered Henry Schein from a "buy" rating to a "hold" rating in a report on Thursday, April 17th. Barrington Research lowered their price objective on Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Piper Sandler reduced their price objective on Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. Finally, UBS Group cut their price target on Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein currently has a consensus rating of "Moderate Buy" and an average target price of $79.30.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.